How much funding has CF PharmTech raised?

CF PharmTech has raised $140.0M in total funding, most recently a Series F round.

Who are CF PharmTech's investors?

CF PharmTech's investors include BioTrack Capital, China Capital Investment Group, New Alliance Capital, Hengxu Capital, CR-CP Life Science Fund, GT Capital.

Where is CF PharmTech headquartered?

CF PharmTech is headquartered in China.

What industry is CF PharmTech in?

CF PharmTech operates in Biotech, Healthcare.

CF PharmTech

长风药业股份有限公司 - 长风药业股份有限公司

China · $140.0M raised

Biotech

Healthcare

Business Model: B2B
Website: cfpharmtech.com
Total Funding: $140.0M

Last Round: $50.0M Series FJun 2020
Rounds: 2

About

CF PharmTech (长风药业, HKEx: 2652.HK) is a China-based publicly listed biopharmaceutical company specializing in inhaled drug delivery formulations. The company focuses on developing and manufacturing inhalation products including dry powder inhalers, nebulizer solutions, nasal sprays, liposomes, and pressurized metered-dose inhalers (pMDIs). CF PharmTech serves patients across respiratory and systemic therapeutic areas, providing innovative inhalation drug delivery technologies for conditions including asthma, COPD, and allergic rhinitis.

Summary

CF PharmTech is a Biotech company based in China. It has raised $140.0M in total across 2 rounds, most recently a $50.0M Series F round in Jun 2020. Investors include BioTrack Capital, China Capital Investment Group and New Alliance Capital.